Quality of care in patients with gout: why is management suboptimal and what can be done about it?
- PMID: 21161617
- DOI: 10.1007/s11926-010-0154-6
Quality of care in patients with gout: why is management suboptimal and what can be done about it?
Abstract
Gout is a common inflammatory arthritis. We know a great deal about its etiopathogenesis and have relatively safe and effective therapies for it. Gout, however, remains a poorly managed disease with mistakes made in securing an accurate diagnosis and in using appropriate therapies for acute and chronic stages of the disease. Synovial fluid analysis with polarizing microscopy is the "gold standard" for confirming the diagnosis of gout but has been used in fewer than 10% of all patients diagnosed with gout. The newly adopted European clinical guidelines offer a practical alternative to synovial fluid analysis, but primary care physicians are not well-versed in their use. Other serious errors in the management of gout are related to the use of medications to treat acute and chronic gout. Frequently, the anti-inflammatory drugs used to treat acute symptoms and urate-lowering drugs used to prevent long-term destruction are improperly dosed, leading to dissatisfaction on the part of patients and physicians. Widespread education about evidence-based diagnostic and treatment guidelines is desperately needed.
Similar articles
-
Gout: a comprehensive review.JAAPA. 2014 Sep;27(9):26-31. doi: 10.1097/01.JAA.0000453233.24754.ec. JAAPA. 2014. PMID: 25102078 Review.
-
Long-term management of gout: nonpharmacologic and pharmacologic therapies.Rheum Dis Clin North Am. 2014 May;40(2):357-74. doi: 10.1016/j.rdc.2014.01.012. Epub 2014 Feb 20. Rheum Dis Clin North Am. 2014. PMID: 24703352 Review.
-
The management of gout at an academic healthcare center in Beijing: a physician survey.J Rheumatol. 2006 Oct;33(10):2041-9. J Rheumatol. 2006. PMID: 17014019
-
Update on emerging urate-lowering therapies.Curr Opin Rheumatol. 2009 Mar;21(2):143-9. doi: 10.1097/BOR.0b013e328325bd94. Curr Opin Rheumatol. 2009. PMID: 19339925 Review.
-
[Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].Orv Hetil. 2018 Oct;159(40):1625-1636. doi: 10.1556/650.2018.31270. Orv Hetil. 2018. PMID: 30277413 Review. Hungarian.
Cited by
-
Adherence to the 2012 American College of Rheumatology (ACR) Guidelines for Management of Gout: A Survey of Brazilian Rheumatologists.PLoS One. 2015 Aug 14;10(8):e0135805. doi: 10.1371/journal.pone.0135805. eCollection 2015. PLoS One. 2015. PMID: 26274585 Free PMC article. Clinical Trial.
-
Goals of gout treatment: a patient perspective.Clin Rheumatol. 2018 Sep;37(9):2557-2566. doi: 10.1007/s10067-018-4243-7. Epub 2018 Aug 4. Clin Rheumatol. 2018. PMID: 30078087
-
Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.Ther Adv Drug Saf. 2017 Dec;8(12):379-388. doi: 10.1177/2042098617727714. Epub 2017 Sep 13. Ther Adv Drug Saf. 2017. PMID: 29204266 Free PMC article. Review.
-
Trends in Gout and Rheumatoid Arthritis Hospitalizations in Canada From 2000 to 2011.Arthritis Care Res (Hoboken). 2017 May;69(5):758-762. doi: 10.1002/acr.23012. Arthritis Care Res (Hoboken). 2017. PMID: 27565008 Free PMC article.
-
The Pyroptotic Cell Death Effector Gasdermin D Is Activated by Gout-Associated Uric Acid Crystals but Is Dispensable for Cell Death and IL-1β Release.J Immunol. 2019 Aug 1;203(3):736-748. doi: 10.4049/jimmunol.1900228. Epub 2019 Jun 17. J Immunol. 2019. PMID: 31209100 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical